Cost-Effectiveness of Capecitabine vs 5-FU/LV in Colon Cancer
Author Information
Author(s): Cassidy J, Douillard J-Y, Twelves C, McKendrick J J, Scheithauer W, Bustová I, Johnston P G, Lesniewski-Kmak K, Jelic S, Fountzilas G, Coxon F, Díaz-Rubio E, Maughan T S, Malzyner A, Bertetto O, Beham A, Figer A, Dufour P, Patel K K, Cowell W, Garrison L P
Primary Institution: Cancer Research UK
Hypothesis
Is adjuvant capecitabine more cost-effective than intravenous 5-FU/LV for Dukes' C colon cancer?
Conclusion
Capecitabine is a cost-saving and more effective treatment compared to 5-FU/LV for Dukes' C colon cancer.
Supporting Evidence
- Capecitabine showed significant superiority in relapse-free survival compared to 5-FU/LV.
- Patients preferred oral capecitabine over intravenous treatments.
- Capecitabine resulted in lower overall medical costs despite higher drug acquisition costs.
Takeaway
Capecitabine is a pill that helps people with colon cancer live longer and costs less than the traditional treatment that requires a needle.
Methodology
A randomized phase III trial comparing capecitabine and 5-FU/LV over 24 weeks in patients with Dukes' C colon cancer.
Limitations
Utility values for health states were imputed rather than directly measured.
Participant Demographics
Patients with Dukes' C colon cancer, enrolled at 164 centers worldwide.
Statistical Information
P-Value
0.0407
Statistical Significance
p=0.0407
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website